Ron Call

A biopharmaceutical giant is investing more than $600 million into an innovative research center at its Southern California headquarters. Amgen #LosAngeles #biotech

4

LABN Trending News: Amgen to expand California headquarters with new $600M R&D center https://lnkd.in/gzhcfEPs Amgen will invest $600 million to expand its headquarters in Thousand Oaks, CA, bringing the industry’s total US manufacturing pledge to nearly $300 billion this year. The expansion will include a new research and development [...]

3

Proud to share that Amgen is investing $650M to expand our Juncos site, creating nearly 750 new jobs and growing our ability to deliver innovative medicines for patients worldwide. For over three decades, Juncos has been home to a world-class team whose dedication and operational excellence continue to make a difference for patients, for Amgen, and for Puerto Rico. This expansion reflects both the strength of our people and the importance of Puerto Rico as a hub for global biomanufacturing. Excited for what’s ahead as we continue to grow together. #mycompany

65

2 Comments

Growth is great! Happy to share Amgen's continued investment in our biopharmaceutical manufacturing here in Puerto Rico. We're excited about the investment to enable advanced technologies to serve our patients and Amgen's volume driven growth. #mycompany https://lnkd.in/gZJcwYxy

46

CSL announces expansion of Illinois plasma therapy manufacturing facility Vertex Biopharm Consulting New $1.5 billion investment builds on over $3 billion already spent on CSL's U.S. operations since 2018 - Expansion will create at least 300 new jobs and enhance production of plasma-derived therapies and albumin through advanced manufacturing capabilities - Governor Pritzker, local officials and CSL leadership underscore the expansion's role in supporting patients and strengthening the regional economy "Illinois is leading the way in life sciences manufacturing, and CSL's $1.5 billion investment is a powerful vote of confidence in our state," said Governor JB Pritzker. "This expansion will create hundreds of good-paying jobs and strengthen domestic supply chains for critical therapies. CSL's continued growth in Kankakee County builds on decades of innovation and manufacturing leadership right here in Illinois. We're proud to partner with CSL as they expand their footprint and deepen their commitment to communities across our state." "For people living with rare diseases like primary immunodeficiency (PI), consistent access to treatment is the foundation that lets them plan their days and their futures," said Jorey Berry, president and CEO, Immunodeficiency Deficiency Foundation. "Manufacturing plasma-derived therapies is a lengthy and complex process, and maintaining reliable supply is an ongoing challenge. Patients depend on meaningful investment from industry partners — and on policies that support, rather than hinder, that commitment. For the Immune Deficiency Foundation, this expansion in Kankakee is a powerful sign that patients' hopes are truly being prioritized." https://lnkd.in/eN96743X

12

The best risk management strategy in biologics manufacturing is prevention — not reaction. In a recent BioPharm International article, Pranav Vengsarkar, Director, Process R&D and Site Head at our Bridgewater Innovation Center, shares why biologics facilities require proactive, risk‑based maintenance programs to control contamination, ensure cGMP compliance and protect patient safety. The article highlights how early mitigation and vigilant maintenance help manufacturers stay inspection‑ready while improving operational resilience. Read the full article to hear Pranav’s perspective on safeguarding biologics manufacturing for the future: https://gag.gl/DJhrHQ

4

The best risk management strategy in biologics manufacturing is prevention — not reaction. In a recent BioPharm International article, Pranav Vengsarkar, Director, Process R&D and Site Head at our Bridgewater Innovation Center, shares why biologics facilities require proactive, risk‑based maintenance programs to control contamination, ensure cGMP compliance and protect patient safety. The article highlights how early mitigation and vigilant maintenance help manufacturers stay inspection‑ready while improving operational resilience. Read the full article to hear Pranav’s perspective on safeguarding biologics manufacturing for the future: https://gag.gl/DJhrHQ

1

I’m proud of this exciting announcement for Amgen: the construction of a new center for science and innovation at our Thousand Oaks headquarters. With flexible lab spaces, cutting-edge automation, and a digital-first infrastructure, this building will redefine how we enable innovation at Amgen. Efforts are also underway to make it the most sustainable building on our Thousand Oaks campus, a reflection of our commitment to continuous improvement in every sense. Amgen’s long-standing commitment to U.S. innovation and state-of-the-art operations is reflected in more than $40 billion invested in manufacturing and research and development. Projects like this don’t happen overnight. They’re the result of years of planning, teamwork, and dedication. I’m deeply grateful to the many colleagues and partners who are making this possible, and I can’t wait to see how this new space empowers our scientists, researchers and engineers to make an even bigger impact for patients worldwide. #MyCompany

379

19 Comments

Today marks an important milestone toward delivering on our commitment to manufacturing all our key medicines end-to-end in the US. We’re proud to cut the ribbon at our new radioligand therapy (RLT) manufacturing site in Carlsbad, California. This facility is more than a manufacturing site—it’s a catalyst for regional growth, bringing high-skilled jobs to the community and strengthening a future-ready supply chain for patients across the Western US and beyond. For the past seven years, Novartis has led the way in RLT because we believe in its power to transform cancer care. Thank you to everyone who is helping bring this vision to life. Together, we’re expanding our ability to meet rising demand and deliver our cutting-edge therapies reliably and at scale to patients in America. Learn more about the progress behind our $23 billion investment in US infrastructure: https://lnkd.in/efRDzBAh

2,335

56 Comments

📢 Seattle Success: 4 FDA-approved biologics in just 2 years, including 2 FC-fusion proteins and a monoclonal antibody. This accomplishment highlights the commitment of AGC Biologics to maintain regulatory compliance and a high level of product quality to help our customers reach commercial success. Read more about our cGMP mammalian and microbial manufacturing capabilities and the exciting biologics in production in Seattle. Find a link in the comments below. #Regulatory #MonoclonalAntibodies #Biotechnology #Biologics #Pharma #Biopharma #yourfriendlyCDMOexpert

105

2 Comments